Drugs / Ad26.Filo
last change Jan 2018 re-read 2 minutes ago

Ad26.Filo

Vaccine

Investigated by
Janssen Vaccines & Prevention B.V. · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02860650 Aug 2016 → May 2017 Janssen Vaccines & Prevention B.V. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Ad26.Filo ClinicalTrials.gov intervention name — accepted as the source's own label NCT02860650
Modality Vaccine “Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules” NCT02860650
Route Intramuscular “Ad26.Filo intramuscular (IM) injection” NCT02860650